Table 5 Overview of adverse events in enrolled women
Adverse event, n (%) | PP analysis | |
|---|---|---|
IPTp-SP n = 124 | ISTp-uRDT-PA n = 126 | |
Number of AEs | 97 | 98 |
Study participants with AEs | 21 (16.9) | 19 (15.1) |
Study participants with SAEs | 19 (15.3) | 11 (8.7) |
Study participants with treatment-related AES | 0 | 0 |
Number of deaths | 0 | 0 |
Study participants who discontinued treatment due to AES | 1 (0.8) | 0 |
Study participants who temporarily discontinued treatment due to AES | 0 | 1 (0.8) |